APH Insider D'Amico Exercises Options and Sells Shares at ~$110.6

Rhea-AI Filing Summary

Lance E. D'Amico, Sr. VP, Secretary & General Counsel of Amphenol Corporation (APH), reported multiple transactions on 08/18/2025. The filing shows exercises of stock options and contemporaneous open-market sales. The reporting person exercised a 100,000-share option at an exercise price of $22.5525 and a 30,000-share option at $22.3725. On the same date the filing reports sales of 100,000 and 30,000 Class A common shares at weighted-average prices of approximately $110.6003 and $110.8083, respectively. The Form 4 indicates various direct and indirect beneficial ownership figures after these transactions, including a reported 25,000 shares indirectly held in a 2025 GRAT.

Positive

• None.

Negative

• Insider sold 130,000 Class A shares (100,000 + 30,000) on 08/18/2025 at weighted-average prices of approximately $110.6003 and $110.8083.
• Direct beneficial ownership declined materially in the reported lines (for example, from 176,400 to 76,400 shares following a sale).

Insights

Financial Analyst

TL;DR: Insider exercised options then sold shares, realizing substantial proceeds; ownership figures shifted between direct and indirect holdings.

The Form 4 documents option exercises and large-volume sales by a senior executive on 08/18/2025. The reporting person exercised a 100,000-share option at $22.5525 and a 30,000-share option at $22.3725, and sold 100,000 and 30,000 shares at weighted-average prices near $110.60 and $110.81. These transactions realize material cash proceeds given the large price spread between exercise price and sale price. The filing also shows subsequent reported beneficial ownership changes, including direct and trust-held positions and a 25,000-share indirect holding in a GRAT. For investors, this is notable insider liquidity, but the filing does not state the use of proceeds or any change to employment or company operations.

Corporate Governance Expert

TL;DR: Insider compliance filing shows option exercises and immediate sales; disclosure appears complete with sale price ranges provided.

The Form 4 includes clear disclosure of option exercise details, sale transaction price ranges, and attribution of indirect holdings to a named irrevocable trust and a GRAT. The explanatory notes specify the sale price ranges and offer to provide trade-level details upon request, which aligns with Section 16 reporting expectations. The filing is signed and dated 08/19/2025. There is no indication in the filing of any Rule 10b5-1 plan checkbox being marked, so the filing does not explicitly assert an affirmative defense under that rule.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

D'AMICO LANCE E

(Last) (First) (Middle)

C/O AMPHENOL CORPORATION

358 HALL AVENUE

(Street)

WALLINGFORD CT 06492

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMPHENOL CORP /DE/ [ APH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP, Secretary & GenCounsel

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/18/2025		M		100,000	A	$22.5525	176,400	D
Class A Common Stock	08/18/2025		S		100,000	D	$110.6003(1)(2)	76,400	D
Class A Common Stock	08/18/2025		M		30,000	A	$22.3725	106,400	I	By Lance E. D'Amico 2024 Irrevocable Trust
Class A Common Stock	08/18/2025		S		30,000	D	$110.8083(1)(3)	76,400	I	By Lance E. D'Amico 2024 Irrevocable Trust
Class A Common Stock								25,000	I	By Lance E. D'Amico 2025 GRAT #1

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$22.5525	08/18/2025		M			100,000	05/21/2021	05/21/2030	Class A Common Stock	100,000	$0	220,000	D
Stock Option	$22.3725	08/18/2025		M			30,000	05/23/2020	05/23/2029	Class A Common Stock	30,000	$0	40,000	I	By Lance E. D'Amico 2024 Irrevocable Trust

Explanation of Responses:

1. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

2. This transaction was executed in multiple trades ranging from $110.5000 to $110.8050.

3. This transaction was executed in multiple trades raging from $110.7100 to $110.9300.

	/s/ Lance E. D'Amico	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did APH insider Lance E. D'Amico report on 08/18/2025?

The Form 4 reports exercises of options for 100,000 and 30,000 shares and contemporaneous sales of 100,000 and 30,000 Class A shares on 08/18/2025.

At what prices were the APH shares sold by the reporting person?

The filing reports weighted-average sale prices of approximately $110.6003 for the 100,000-share sale and $110.8083 for the 30,000-share sale, with disclosed trade ranges in the explanation.

What were the exercise prices for the stock options exercised by the reporting person?

The exercised options had exercise prices of $22.5525 (100,000 shares) and $22.3725 (30,000 shares).

Did the Form 4 disclose indirect holdings or trust ownership?

Yes. The filing attributes certain shares to the Lance E. D'Amico 2024 Irrevocable Trust and discloses 25,000 shares indirectly held via a 2025 GRAT.

Is there an assertion of a Rule 10b5-1 trading plan in this Form 4?

The filing does not indicate that a checkbox for a Rule 10b5-1(c) plan was marked; no affirmative defense under Rule 10b5-1 is asserted in the disclosed fields.